Evidence map›Paper›PMID 40626718›Full record

ArticleJournal of virology2025

Targeting papillomavirus infections: high-throughput screening reveals an effective inhibitor of cutaneous β-HPV types.

Ruslan Ibragimov, Sofiya Babok, Elina Lototskaja-Perepelenko, Larisa Ivanova, Nika Mikhailava, Lidiia Zaikina, Marko Piirsoo, Alla Piirsoo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ruslan Ibragimov *Institute of Technology, University of Tartu, Tartu, Estonia.
Sofiya Babok *Institute of Technology, University of Tartu, Tartu, Estonia.
Elina Lototskaja-PerepelenkoInstitute of Technology, University of Tartu, Tartu, Estonia.
Larisa IvanovaInstitute of Chemistry, University of Tartu, Tartu, Estonia.
Nika MikhailavaInstitute of Technology, University of Tartu, Tartu, Estonia.
Lidiia ZaikinaInstitute of Technology, University of Tartu, Tartu, Estonia.
Marko PiirsooInstitute of Technology, University of Tartu, Tartu, Estonia.
Alla PiirsooInstitute of Technology, University of Tartu, Tartu, Estonia.ORCID 0000-0001-6843-7127

Funding

Estonian Research Competency Council PRG198University of Tartu PLTTI23911
6 · The paper itself

Abstract

Cutaneous and mucosal human papillomaviruses (HPVs) are implicated in the development of various cancers. To date, there are no HPV-specific antivirals, and vaccines designed for mucosal HPV types are ineffective against cutaneous HPV variants and ongoing infections. These facts, along with the increasing prevalence of specific types of HPV-positive cancers, underscore the unmet need for HPV antiviral drugs. In this study, we performed a high-throughput screening using the National Cancer Institute Diversity Set VI library of small-molecule compounds and identified 5,7-dimethoxy-2-pyridin-3-ylchromen-4-one (NSC51349) as a potent inhibitor of oncogenic cutaneous HPV5 replication in U2OS cells. Further analysis showed that NSC51349 specifically inhibits replication of the HPV5 genome in human primary keratinocytes (IC50 ≈ 4 µM) without detrimental effects on cell cycle, viability, or differentiation. In addition, this compound efficiently inhibits replication of the other cutaneous HPV types 8 and 38, and

Indexed as

Antiviral AgentsBetapapillomavirusPapillomavirus InfectionsAnimalsCell Line, TumorHigh-Throughput Screening AssaysHumansKeratinocytesMolecular Docking SimulationOncogene Proteins, ViralSmall Molecule LibrariesVirus ReplicationAntiviral AgentsOncogene Proteins, ViralSmall Molecule LibrariesE2 proteinhigh-throughput screeninghuman papillomavirusinhibitionreplication

Identifiers

PMID40626718
PMCPMC12363231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.